Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.63 |
| ▸ | EBP | Q15125 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13223790 | 1.00 | SIGMAR1 (0.63) | SIGMAR1EBPKDM4ETDP1ALDH1A1 | |
| SCHEMBL11122622 | 0.98 | SIGMAR1 (0.67) | SIGMAR1EBPKDM4ETDP1ALDH1A1 | |
| SCHEMBL9361316 | 0.98 | SIGMAR1 (0.67) | SIGMAR1EBPKDM4ETDP1ALDH1A1 | |
| SCHEMBL10812144 | 0.98 | SIGMAR1 (0.67) | SIGMAR1EBPKDM4ETDP1ALDH1A1 | |
| SCHEMBL16943589 | 0.94 | SIGMAR1 (0.60) | SIGMAR1EBPKDM4ETDP1ALDH1A1 | |
| SCHEMBL21566192 | 0.94 | SIGMAR1 (0.60) | SIGMAR1EBPKDM4ETDP1ALDH1A1 | |
| SCHEMBL24936742 | 0.85 | SIGMAR1 (0.53) | SIGMAR1EBPKDM4ETDP1ALDH1A1 | |
| SCHEMBL13519646 | 0.85 | SIGMAR1 (0.53) | SIGMAR1EBPKDM4ETDP1ALDH1A1 | |
| SCHEMBL13995262 | 0.85 | SIGMAR1 (0.53) | SIGMAR1EBPKDM4ETDP1ALDH1A1 | |
| SCHEMBL25446590 | 0.85 | SIGMAR1 (0.53) | SIGMAR1EBPKDM4ETDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873709-B2 | Triazolopyridine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | SIGMAR1 1063/4885EBP 3909/4885KDM4E 1708/4885 |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | SIGMAR1 690/4885EBP 504/4885KDM4E 2800/4885 |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | SIGMAR1 1063/4885EBP 3909/4885KDM4E 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.